NCT07838506Phase 3Not yet recruiting

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

Study sponsor: Okyo Pharma Ltd · OKYO

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05Estimated
Enrollment · participants111Estimated
Source updated2026-09-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: The change from baseline at Week 12 in ocular pain assessed by VAS score. Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12.. After: Measure: The change from baseline at Week 12 in ocular pain assessed by Visual Analogue Scale (0-10) score. (Score of 10 is "worst possible pain".) Description: Evaluate the efficacy and safety of urcosimod 0.05% as compared to placebo instilled 4 times/day in participants who have a documented ocular history of symptoms of neuropathic corneal pain. Time frame: From baseline (time of randomization) compared to Week 12..

Check registry source